The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases

Acta Pharmaceutica Sinica B

Volumn 6, Issue 3, 2016, Pages 183-188

  Chen, Qingjie ^a,b   Guan, Xiaofeng ^a   Zuo, Xiaocong ^a,b   Wang, Jianglin ^a   Yin, Wenjun ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Acute kidney injury; Antineutrophil cytoplasmic autoantibody associated vasculitis; Chronic kidney disease; Clear cell renal cell carcinoma; Diabetic nephropathy; High mobility group box 1; Inflammation; Nephritis

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALARMIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N(G),N(G) DIMETHYLARGININE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE KIDNEY FAILURE; ANCA ASSOCIATED VASCULITIS; APOPTOSIS; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; GRANULOMATOUS NEPHRITIS; HUMAN; INNATE IMMUNITY; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE ACTIVATION; NEPHRITIS; NONHUMAN; PATHOGENESIS; REVIEW;

EID: 84971569480     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2016.02.004     Document Type: Review

References (56)

1. Kurts C., Panzer U., Anders H.J., Rees A.J. The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol 2013, 13:738-753.
2. Goodwin G.H., Sanders C., Johns E.W. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 1973, 38:14-19.
3. Tang D.L., Kang R., Livesey K.M., Kroemer G., Billiar T.R., van Houten B., et al. High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab 2011, 13:701-711.
4. Tsung A., Tohme S., Billiar T.R. High-mobility group box-1 in sterile inflammation. J Intern Med 2014, 276:425-443.
5. Bonaldi T., Talamo F., Scaffidi P., Ferrera D., Porto A., Bachi A., et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003, 22:5551-5560.
6. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
7. Celona B., Weiner A., di Felice F., Mancuso F.M., Cesarini E., Rossi R.L., et al. Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output. PLoS Biol 2011, 9:e1001086.
8. Tang D.L., Kang R., Livesey K.M., Zeh H.J., Lotze M.T. High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal 2011, 15:2185-2195.
9. Tang D.L., Kang R., Cheh C.W., Livesey K.M., Liang X., Schapiro N.E., et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010, 29:5299-5310.
10. Tang D.L., Kang R., Livesey K.M., Cheh C.W., Farkas A., Loughran P., et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010, 190:881-892.
11. Liu Y.S., Song L.J. HMGB1-induced autophagy in Schwann cells promotes neuroblastoma proliferation. Int J Clin Exp Pathol 2015, 8:504-510.
12. Widlak P., Garrard W.T. Discovery regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G. J Cell Biochem 2005, 94:1078-1087.
13. Narumi T., Shishido T., Otaki Y., Kadowaki S., Honda Y., Funayama A., et al. High-mobility group box 1-mediated heat shock protein beta 1 expression attenuates mitochondrial dysfunction and apoptosis. J Mol Cell Cardiol 2015, 82:1-12.
14. Andersson U., Antoine D.J., Tracey K.J. The functions of HMGB1 depend on molecular localization and post-translational modifications. J Intern Med 2014, 276:420-424.
15. Huttunen H.J., Fages C., Kuja-Panula J., Ridley A.J., Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Rets 2002, 62:4805-4811.
16. Park J.S., Gamboni-Robertson F., He Q., Svetkauskaite D., Kim J.Y., Strassheim D., et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006, 29:C917-C924.
17. Campana L., Bosurgi L., Bianchi M.E., Manfredi A.A., Rovere-Querini P. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J Leukoc Biol 2009, 86:609-615.
18. Chen M., Liu Y., Varley P., Chang Y., He X.X., Huang H., et al. High mobility group box-1 promotes hepatocellular carcinoma progression through miR-21-mediated matrix metalloproteinase activity. Cancer Res 2015, 75:1645.
19. Bruchfeld A., Wendt M., Bratt J., Qureshi A.R., Chavan S., Tracey K.J., et al. High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 2011, 17:29-35.
20. Wang C., Gou S.J., Chang D.Y., Yu F., Zhao M.H., Chen M. Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Care Res 2013, 65:1828-1834.
21. Rabadi M.M., Ghaly T., Goligorksy M.S., Ratliff B.B. HMGB1 in renal ischemic injury. Am J Physiol Ren Physiol 2012, 303:F873-F885.
22. Takeuchi T., Sakazume K., Tonooka A., Zaitsu M., Takeshima Y., Mikami K., et al. Cytosolic HMGB1 expression in human renal clear cell cancer indicates higher pathological T classifications and tumor grades. Urol J 2013, 10:960-965.
23. Zakiyanov O., Kriha V., Vachek J., Zima T., Tesar V., Kalousova M. Placental growth factor, pregnancy-associated plasma protein-a, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study. BMC Nephrol 2013, 14:245.
24. Leelahavanichkul A., Huang Y.N., Hu X.Z., Zhou H., Tsuji T., Chen R., et al. Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing high mobility group box protein-1. Kidney Int 2011, 80:1198-1211.
25. Bruchfeld A., Qureshi A.R., Lindholm B., Barany P., Yang L.H., Stenvinkel P., et al. High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 2008, 14:109-115.
26. Ali B.H., Al Z.M., Al S.A., Nemmar A. High-mobility group box-1 protein in adenine-induced chronic renal failure and the influence of gum arabic thereon. Physiol Res 2015, 64:147-151.
27. Li X.Y., Yue Y., Zhu Y.Y., Xiong S.D. Extracellular, but not intracellular HMGB1, facilitates self-DNA induced macrophage activation via promoting DNA accumulation in endosomes and contributes to the pathogenesis of lupus nephritis. Mol Immunol 2015, 65:177-188.
28. Abdulahad D.A., Westra J., Bijzet J., Limburg P.C., Kallenberg C.G.M., Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:R71.
29. Zickert A., Palmblad K., Sundelin B., Chavan S., Tracey K.J., Bruchfeld A., et al. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther 2012, 14:R36.
30. Abdulahad D.A., Westra J., Bijzet J., Dolff S., van Dijk M.C., Limburg P.C., et al. Urine levels of HMGB1 in systemic lupus erythematosus patients with and without renal manifestations. Arthritis Res Ther 2012, 14:R184.
31. Oyama Y., Hashiguchi T., Taniguchi N., Tancharoen S., Uchimura T., Biswas K.K., et al. High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. Lab Invest 2010, 90:853-866.
32. Lynch J., Nolan S., Slattery C., Feighery R., Ryan M.P., McMorrow T. High-mobility group box protein 1: a novel mediator of inflammatory-induced renal epithelial-mesenchymal transition. Am J Nephrol 2010, 32:590-602.
33. Tian S.J., Zhang L., Tang J.M., Guo X., Dong K., Chen S.Y. HMGB1 exacerbates renal tubulointerstitial fibrosis through facilitating M1 macrophage phenotype at the early stage of obstructive injury. Am J Physiol Ren Physiol 2015, 308:F69-75.
34. Kim J., Sohn E., Kim C.S., Jo K., Kim J.S. The role of high-mobility group box-1 protein in the development of diabetic nephropathy. Am J Nephrol 2011, 33:524-529.
35. Hoste E.A., Clermont G., Kersten A., Venkataraman R., Angus D.C., De Bacquer D., et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006, 10:R73.
36. Glodowski S.D., Wagener G. New insights into the mechanisms of acute kidney injury in the intensive care unit. J Clin Anesth 2015, 27:175-180.
37. Wu H.L., Ma J., Wang P., Corpuz T.M., Panchapakesan U., Wyburn K.R., et al. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 2010, 21:1878-1890.
38. Wu H.L., Steenstra R., de Boer E.C.S., Zhao C.Y., Ma J., van der Stelt J.M., et al. Preconditioning with recombinant high-mobility group box 1 protein protects the kidney against ischemia-reperfusion injury in mice. Kidney Int 2014, 85:824-832.
39. Zhang Y.X., Zhang J.R., Wang Z.G. Mycophenolate mofetil affects monocyte Toll-like receptor 4 signaling during mouse renal ischemia/reperfusion injury. Chin Med J (Engl) 2013, 126:1224-1229.
40. Ruan Y.L., Wang L., Zhao Y., Yao Y., Chen S., Li J.H., et al. Carbon monoxide potently prevents ischemia-induced high-mobility group box 1 translocation and release and protects against lethal renal ischemia-reperfusion injury. Kidney Int 2014, 86:525-537.
41. Lau A., Wang S., Liu W., Haig A., Zhang Z.X., Jevnikar A.M. Glycyrrhizic acid ameliorates HMGB1-mediated cell death and inflammation after renal ischemia reperfusion injury. Am J Nephrol 2014, 40:84-95.
42. Bao Y.S., Na S.P., Zhang P., Jia X.B., Liu R.C., Yu C.Y., et al. Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. J Clin Immunol 2012, 32:587-594.
43. Sato F., Maruyama S., Hayashi H., Sakamoto I., Yamada S., Uchimura T., et al. High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract 2008, 108:C194-C201.
44. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Ueda Y., Suzuki T., et al. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism 2009, 58:1624-1628.
45. Lan H.Y. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003, 12:25-29.
46. Leemans J.C., Butter L.M., Pulskens W.P.C., Teske G.J.D., Claessen N., van der Poll T., et al. The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury. PLoS One 2009, 4:e5704.
47. King G.L. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008, 79:1527-1534.
48. Lin M., Yiu W.H., Wu H.J., Chan L.Y.Y., Leung J.C.K., Au W.S., et al. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 2012, 23:86-102.
49. Mudaliar H., Pollock C., Komala M.G., Chadban S., Wu H.L., Panchapakesan U., et al. The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules. Am J Physiol Ren Physiol 2013, 305:F143-F154.
50. Mudaliar H., Pollock C., Ma J., Wu H.L., Chadban S., Panchapakesan U., et al. The role of TLR2 and 4-mediated inflammatory pathways in endothelial cells exposed to high glucose. PLoS One 2014, 9:e108844.
51. Wu F., Zhao Z.H., Ding S.T., Wu H.H., Lu J.J. High mobility group box 1 protein is methylated and transported to cytoplasm in clear cell renal cell carcinoma. Asian Pac J Cancer Prev 2013, 14:5789-5795.
52. Lin L.G., Zhong K.H., Sun Z.K., Wu G.Z., Ding G.D. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol 2012, 138:11-22.
53. Zickert A., Palmblad K., Sundelin B., Chavan S., Tracey K.J., Bruchfeld A., et al. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther 2012, 14:R36.
54. Abdulahad D.A., Westra J., Bijzet J., Limburg P.C., Kallenberg C.G., Bijl M., et al. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:R71.
55. Zickert A., Palmblad K., Sundelin B., Chavan S., Tracey K.J., Bruchfeld A., et al. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther 2012, 14:R36.
56. Abdulahad D.A., Westra J., Bijzet J., Dolff S., van Dijk M.C., Limburg P.C., et al. Urine levels of HMGB1 in systemic lupus erythematosus patients with and without renal manifestations. Arthritis Res Ther 2012, 14:R184.